Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 1
2018 3
2019 2
2020 17
2021 20
2022 26
2023 28
2024 27
2025 27
2026 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

149 results

Results by year

Filters applied: . Clear all
Page 1
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I; IRONMAN Study Group. Kalra PR, et al. Lancet. 2022 Dec 17;400(10369):2199-2209. doi: 10.1016/S0140-6736(22)02083-9. Epub 2022 Nov 5. Lancet. 2022. PMID: 36347265 Free article. Clinical Trial.
Intravenous ferric derisomaltose dose was determined by patient bodyweight and haemoglobin concentration. ...INTERPRETATION: For a broad range of patients with heart failure, reduced left ventricular ejection fraction and iron deficiency, intravenous …
Intravenous ferric derisomaltose dose was determined by patient bodyweight and haemoglobin concentration. ...INTERPRETATION: F …
Intravenous ferric derisomaltose for the treatment of iron deficiency anemia.
Auerbach M, Henry D, DeLoughery TG. Auerbach M, et al. Am J Hematol. 2021 Jun 1;96(6):727-734. doi: 10.1002/ajh.26124. Epub 2021 Feb 26. Am J Hematol. 2021. PMID: 33580972 Free PMC article. Review.
One such formulation, ferric derisomaltose, has been approved in the United States for delivery of 1000 mg iron in a single IV infusion. Ferric derisomaltose rapidly repletes iron parameters with low rates of serious or severe HSRs. ...
One such formulation, ferric derisomaltose, has been approved in the United States for delivery of 1000 mg iron in a si …
Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
Zoller H, Wolf M, Blumenstein I, Primas C, Lindgren S, Thomsen LL, Reinisch W, Iqbal T. Zoller H, et al. Gut. 2023 Apr;72(4):644-653. doi: 10.1136/gutjnl-2022-327897. Epub 2022 Sep 9. Gut. 2023. PMID: 36343979 Free PMC article. Clinical Trial.
OBJECTIVE: Intravenous iron-a common treatment for anaemia and iron deficiency due to inflammatory bowel disease (IBD)-can cause hypophosphataemia. ...Adults with IBD and iron deficiency anaemia (IDA) were randomised 1:1 to receive FCM or FDI at …
OBJECTIVE: Intravenous iron-a common treatment for anaemia and iron deficiency due to inflammatory bowel disease (IBD)- …
Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, Thomsen LL, Carpenter TO, Weber T, Brandenburg V, Zoller H. Wolf M, et al. JAMA. 2020 Feb 4;323(5):432-443. doi: 10.1001/jama.2019.22450. JAMA. 2020. PMID: 32016310 Free PMC article. Clinical Trial.
IMPORTANCE: Intravenous iron enables rapid correction of iron-deficiency anemia, but certain formulations induce fibroblast growth factor 23-mediated hypophosphatemia. ...CONCLUSIONS AND RELEVANCE: In 2 randomized trials of patients with iron-defici …
IMPORTANCE: Intravenous iron enables rapid correction of iron-deficiency anemia, but certain formulations induce fibrob …
Ferric Derisomaltose for Heart Failure and Iron Deficiency: Drugs.
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2026 Feb. Report No.: RC1590. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2026 Feb. Report No.: RC1590. PMID: 42118883 Free Books & Documents. Review.
It is not known how well ferric derisomaltose works or how safe it is compared with ferric carboxymaltose or other IV iron treatments in adults with heart failure and iron deficiency. ...It is not known how well ferric derisomaltose …
It is not known how well ferric derisomaltose works or how safe it is compared with ferric carboxymaltose or other IV iron …
Intravenous ferric derisomaltose versus oral iron for persistent iron deficient pregnant women: a randomised controlled trial.
Hansen R, Sommer VM, Pinborg A, Krebs L, Thomsen LL, Moos T, Holm C. Hansen R, et al. Arch Gynecol Obstet. 2023 Oct;308(4):1165-1173. doi: 10.1007/s00404-022-06768-x. Epub 2022 Sep 15. Arch Gynecol Obstet. 2023. PMID: 36107229 Free PMC article. Clinical Trial.

PURPOSE: To compare the efficacy of intravenous (IV) iron (ferric derisomaltose) with oral iron (ferrous fumarate) in women 14-21 weeks pregnant with persistent iron deficiency (ferritin < 30 g/L). ...CONCLUSION: IV iron was su

…
PURPOSE: To compare the efficacy of intravenous (IV) iron (ferric derisomaltose) with oral iron (ferrous fumarat …
Single-dose intravenous iron vs oral iron for treatment of maternal iron deficiency anemia: a randomized clinical trial.
Derman RJ, Bellad MB, Somannavar MS, Bhandari S, Mehta S, Mehta S, Sharma DK, Yogeshkumar S, Charantimath U, Patil AP, Mallapur AA, Ramadurg U, Sangavi R, Patil PS, Roy S, Vastrad P, Shekhar C, Leiby BE, Hartman RL, Georgieff M, Mennemeyer S, Aghai Z, Thind S, Boelig RC; RAPIDIRON Trial Group (Appendix). Derman RJ, et al. Am J Obstet Gynecol. 2025 Aug;233(2):120.e1-120.e18. doi: 10.1016/j.ajog.2025.01.037. Epub 2025 Feb 3. Am J Obstet Gynecol. 2025. PMID: 39909327 Clinical Trial.
Obstetric guidelines advocate for first-line treatment of moderate iron deficiency anemia with twice-daily oral iron; however, rates of iron deficiency anemia in pregnancy remain above global targets and are rising. ...Participants were singleto …
Obstetric guidelines advocate for first-line treatment of moderate iron deficiency anemia with twice-daily oral iron; h …
Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review.
Bazeley JW, Wish JB. Bazeley JW, et al. Am J Kidney Dis. 2022 Jun;79(6):868-876. doi: 10.1053/j.ajkd.2021.09.017. Epub 2021 Nov 7. Am J Kidney Dis. 2022. PMID: 34758368 Free article. Review.
Iron deficiency commonly contributes to the anemia affecting individuals with chronic kidney disease. This review describes diagnostic criteria for iron deficiency in chronic kidney disease, as well as mechanisms of functional and absolute iron …
Iron deficiency commonly contributes to the anemia affecting individuals with chronic kidney disease. This review describes di …
Treating iron deficiency in patients with heart failure: what, why, when, how, where and who.
Graham FJ, Guha K, Cleland JG, Kalra PR. Graham FJ, et al. Heart. 2024 Sep 25;110(20):1201-1207. doi: 10.1136/heartjnl-2022-322030. Heart. 2024. PMID: 39160066 Free PMC article. Review.
Iron deficiency can be swiftly, effectively and safely treated by administering intravenous iron, either as ferric carboxymaltose or ferric derisomaltose, which improves patient well-being and reduces the risk of hospitalisations including those …
Iron deficiency can be swiftly, effectively and safely treated by administering intravenous iron, either as ferric carb …
Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia.
Pollock RF, Biggar P. Pollock RF, et al. Expert Rev Hematol. 2020 Feb;13(2):187-195. doi: 10.1080/17474086.2020.1709437. Epub 2020 Jan 11. Expert Rev Hematol. 2020. PMID: 31928094 Free article. Review.
Objectives: The benefits of intravenous (IV) iron greatly outweigh the risks, but IV iron formulations carry a small risk of hypersensitivity reactions (HSRs). The objective was to use standardized Medical Dictionary for Regulatory Activities queries (SMQs) to compa …
Objectives: The benefits of intravenous (IV) iron greatly outweigh the risks, but IV iron formulations carry a small risk of h …
149 results